{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T17:41:21Z","timestamp":1784655681946,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016579","name":"Amgen Astellas Biopharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00774-025-01651-6","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T11:19:08Z","timestamp":1761650348000},"page":"611-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment with romosozumab in patients with osteoporosis on maintenance hemodialysis"],"prefix":"10.1007","volume":"43","author":[{"given":"Motohiko","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"1651_CR1","volume-title":"Medical guide for fracture risk in lifestyle-related diseases 2019","author":"Japan Osteoporosis, Society Committee on Fracture Risk in Lifestyle-related Diseases","year":"2019","unstructured":"Japan Osteoporosis, Society Committee on Fracture Risk in Lifestyle-related Diseases (2019) Medical guide for fracture risk in lifestyle-related diseases 2019. Life Science Publishing, Japan"},{"key":"1651_CR2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1681\/ASN.2006050546","volume":"18","author":"LF Fried","year":"2007","unstructured":"Fried LF, Biggs ML, Shlipak MG, Seliger S, Kestenbaum B, Stehman-Breen C, Sarnak M, Siscovick D, Harris T, Cauley J, Newman AB, Robbins J (2007) Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol 18:282\u2013286","journal-title":"J Am Soc Nephrol"},{"key":"1651_CR3","volume-title":"Guideline for prevention and treatment of osteoporosis 2015","author":"Japan Osteoporosis Society","year":"2015","unstructured":"Japan Osteoporosis Society (2015) Guideline for prevention and treatment of osteoporosis 2015. Life Science Publishing, Japan"},{"key":"1651_CR4","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"1651_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"1651_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","volume":"103","author":"H Ishibashi","year":"2017","unstructured":"Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone 103:209\u2013215","journal-title":"Bone"},{"key":"1651_CR7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2215\/CJN.06550810","volume":"6","author":"D Cejka","year":"2011","unstructured":"Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH (2011) Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 6:877\u2013882","journal-title":"Clin J Am Soc Nephrol"},{"key":"1651_CR8","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s00774-021-01253-y","volume":"39","author":"M Sato","year":"2021","unstructured":"Sato M, Inaba M, Yamada S, Emoto M, Ohno Y, Tsujimoto Y (2021) Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study. J Bone Miner Metab 39:1082\u20131090","journal-title":"J Bone Miner Metab"},{"key":"1651_CR9","first-page":"396","volume":"7","author":"M Sato","year":"2021","unstructured":"Sato M (2021) Study on the efficacy and safety of romosozumab for dialysis patients with osteoporosis. J Japan Osteopor Soc 7:396\u2013401","journal-title":"J Japan Osteopor Soc"},{"key":"1651_CR10","unstructured":"Sato M, Ubai T (2022) Study on the efficacy and sequential therapy of romosozumab in dialysis patients with osteoporosis. Aijinkai igaku kenkyuusi 54: 31\u201333."},{"key":"1651_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2022.101639","volume":"17","author":"M Ogata","year":"2022","unstructured":"Ogata M, Ushimaru S, Fujishima R, Sumi H, Shiizaki K, Tominaga N (2022) Romosozumab improves low bone mineral density in a postmenopausal woman undergoing chronic hemodialysis and treated with a calcium-sensing receptor agonist. Bone Rep 17:101639","journal-title":"Bone Rep"},{"key":"1651_CR12","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"1651_CR13","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","volume":"119","author":"Z Carmine","year":"2023","unstructured":"Carmine Z, Francesca M, Marcin A, Rodrigo BO, Ziad AM, Pantelis S, Rajiv A, Patrick BM, Peter K, Charles JF, Christoph W, Michel B, Raymond V, Andrzej W (2023) Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovasc Res 119:2017\u20132032","journal-title":"Cardiovasc Res"},{"key":"1651_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/jbmr\/zjae194","volume":"40","author":"MR McClung","year":"2025","unstructured":"McClung MR, Betah D, Leder BZ, Kendler DL, Oates M, Timoshanko J, Wang Z (2025) Romosozumab improves microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis. J Bone Miner Res 40:193\u2013200","journal-title":"J Bone Miner Res"},{"key":"1651_CR15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2106\/JBJS.19.00790","volume":"102","author":"EH Schemitsch","year":"2020","unstructured":"Schemitsch EH, Miclau T, Karachalios T, Nowak LL, Sancheti P, Poolman RW, Caminis J, Daizadeh N, Dent-Acosta RE, Egbuna O, Chines A, Maddox J, Grauer A, Bhandari M (2020) A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures. J Bone Joint Surg Am 102:693\u2013702","journal-title":"J Bone Joint Surg Am"},{"key":"1651_CR16","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.2106\/JBJS.19.01008","volume":"102","author":"M Bhandari","year":"2020","unstructured":"Bhandari M, Schemitsch EH, Karachalios T, Sancheti P, Poolman RW, Caminis J, Daizadeh N, Dent-Acosta RE, Egbuna O, Chines A, Miclau T (2020) Romosozumab in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture: a randomized phase-2 study. J Bone Joint Surg Am 102:1416\u20131426","journal-title":"J Bone Joint Surg Am"},{"key":"1651_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00223-022-01031-6","volume":"112","author":"T Saito","year":"2023","unstructured":"Saito T, Mizobuchi M, Kato T, Suzuki T, Fujiwara Y, Kanamori N, Makuuchi M, Honda H (2023) One-year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study. Calcif Tissue Int 112:34\u201344","journal-title":"Calcif Tissue Int"},{"key":"1651_CR18","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s00198-021-05927-1","volume":"32","author":"H Hagino","year":"2021","unstructured":"Hagino H, Tanaka K, Silverman S, McClung M, Gandra SR, Charokopou M, Adachi K, Johnson B, Stollenwerk B (2021) Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan. Osteoporos Int 32:2011\u20132021","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01651-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-025-01651-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01651-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:55:08Z","timestamp":1773341708000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-025-01651-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1651"],"URL":"https:\/\/doi.org\/10.1007\/s00774-025-01651-6","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. S. has received speaking fee from Amgen Inc..","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was approved by the Ethics Review Committee of Inoue Hospital (Approval #250) and conducted in accordance with the principles of the Declaration of Helsinki. All patients provided consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided consent to participate in this study and written informed consent was obtained from each participant prior to participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}